Pharma producer Sabaa International Company announced it signed an agreement with the national health insurance and the Liver Institute to supply 450k packets of its hepatitis C treatment Sofoheb, according to an EGX disclosure. The agreement is worth EGP 135 mn approximately and lasts until mid-2018. Sabaa expects the agreement to contribute at least EGP 12 mn to its income.
More from Enterprise
Banks threaten to look beyond London as windfall tax talk grows
International lenders say more tax could tip the balance as…
Granite is about to test whether Egypt’s funds still need administrators
The asset manager and blockchain builder Tarmiiz have entered the…
Inside the retail wave reshaping EGX
Individuals are setting EGX prices day to day, trading on…
Egyptian-UK fintech Zeal raises USD 10 mn to back expansion plans
The London-based, Egyptian-founded fintech is preparing to activate its loyalty…